For people with polycythemia vera, the standard of care has long involved showing up to have blood removed. Not once, but repeatedly, sometimes every few weeks, for years, because thinning the blood is the most direct way to keep clots, strokes, and heart attacks at bay.
The Food and Drug Administration has now approved a drug aimed squarely at that routine. Mimrylo, known generically as rusfertide, was cleared on August 28 to treat the overproduction of red blood cells in adults with polycythemia vera. In its pivotal trial, 76.9 percent of patients taking it needed no therapeutic blood draws over a 32-week stretch, compared with 32.9 percent on placebo.
Polycythemia vera affects an estimated 90,000 people in the United States. It is a chronic condition in which bone marrow overproduces red blood cells, thickening the blood and raising the risk of stroke, deep vein thrombosis, and pulmonary embolism. It is classified as a blood cancer, specifically a myeloproliferative neoplasm, though the FDA's own announcement describes it more plainly as a rare blood disorder.
The Phlebotomy Burden This Targets
The primary treatment goal in polycythemia vera is keeping hematocrit, the proportion of red blood cells in blood, below 45 percent. Uncontrolled hematocrit is associated with a substantially higher risk of cardiovascular death and major cardiovascular events.
Getting there usually means therapeutic phlebotomy, which is the deliberate removal of blood, sometimes combined with drugs that reduce cell production. It works, but it is demanding. Patients build their calendars around appointments, and repeated blood removal drives iron deficiency, which contributes to the fatigue, difficulty concentrating, itching, and night sweats that many describe as the worst part of living with the disease.
Existing therapy does not solve the problem for most people. According to figures cited in Takeda's announcement, an estimated 78 percent of patients continue to have uncontrolled hematocrit despite standard care.
Tanya Wroblewski, director of the Division of Nonmalignant Hematology at the FDA's Center for Drug Evaluation and Research, said in the agency's announcement that the approval "offers a new, first-in-class option that has the potential to meaningfully reduce patient burden."
Inside the VERIFY Trial
The approval rests on VERIFY, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of 293 adults with polycythemia vera who required frequent phlebotomy despite ongoing standard care.
Participants were randomized one-to-one. Treatment started at 19 mg given by injection under the skin once weekly and was adjusted to hold hematocrit below 45 percent. The primary measure was the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32.
That endpoint clearly favored the drug: 76.9 percent versus 32.9 percent. Takeda also reports improvement on a standard fatigue measure, and says the drug was generally well tolerated through 52 weeks.
The most common adverse reactions were injection site reactions, reported in 56 percent of treated patients, and anemia, reported in 16 percent. Anemia is worth pausing on, since the drug works by restricting iron availability, and the same mechanism that curbs red cell overproduction can push some patients too far in the other direction. The label also warns that the drug may raise platelet counts, which is why blood counts need checking every two to four weeks after starting and during dose changes. Because animal studies indicated possible fetal harm, the label advises pregnancy testing before treatment and effective contraception during it.
The trial is ongoing in an open-label extension, and longer-term data have not yet been published. Importantly, the study measured phlebotomy avoidance and hematocrit control, not clot or stroke events. Whether reduced phlebotomy translates into fewer cardiovascular events is a reasonable expectation but not something these data establish.
Iron, Hepcidin, and a Different Mechanism
Hepcidin is a hormone the body uses to regulate where iron goes. In polycythemia vera, iron flows into the bone marrow and fuels red cell production while other tissues run short, which is why patients can be simultaneously overproducing red cells and iron deficient elsewhere.
Mimrylo mimics hepcidin. By limiting the iron available for making new red blood cells, it reduces the overproduction at its source rather than removing the cells after the fact. According to the full prescribing information, it is given once weekly by injection under the skin.
The drug was discovered by Protagonist Therapeutics, which led development through phase 3. Takeda now holds exclusive global development and commercialization rights. Both companies have an interest in how the results are framed, which is worth keeping in mind when reading launch materials.
Access Questions and Who Should Ask Them
The drug received priority review and is administered as a weekly injection under the skin, which means it does not require an infusion center visit.
No consumer-facing list price was available at the time of writing, and formulary decisions at most plans will not have been made yet. Specialty injectables of this kind typically carry prior authorization requirements, and patients should expect that step.
The people most likely to be candidates are adults whose hematocrit stays above 45 percent despite phlebotomy and cell-reducing therapy, and those whose phlebotomy schedule is frequent enough to disrupt work or caregiving. That is a conversation for a hematologist, not a decision to make from an article.
Patients should not stop existing therapy. Phlebotomy and cell-reducing drugs remain the established approach, and the new drug was studied as an addition to ongoing standard care rather than a replacement for it.
Anyone with polycythemia vera who develops sudden severe headache, one-sided weakness, trouble speaking, chest pain, shortness of breath, or painful swelling in one leg should seek emergency care without waiting for a scheduled appointment. Those are signs of the clotting events that the whole treatment strategy exists to prevent, and they are time-sensitive. Cardiovascular risk is under active study across several drug classes, including a diabetes drug now cleared to lower heart attack risk.
Takeda says it is pursuing regulatory reviews outside the United States and plans to present further data at upcoming medical meetings. MedicalDaily will track coverage decisions and longer-term safety findings.
Key Questions Answered
What was approved? Mimrylo, generically rusfertide, for adults with polycythemia vera, targeting the overproduction of red blood cells. The FDA cleared it on August 28 under priority review.
What is polycythemia vera? A chronic condition in which bone marrow overproduces red blood cells, thickening the blood and raising the risk of stroke, deep vein thrombosis, and pulmonary embolism. It affects an estimated 90,000 people in the United States.
How well did it work? In the 293-patient VERIFY trial, 76.9 percent of treated patients required no phlebotomy over the 32-week period, compared with 32.9 percent on placebo.
How is it taken? An injection under the skin once weekly, starting at 19 mg and adjusted to keep hematocrit below 45 percent.
What are the side effects? Injection site reactions and anemia were most common. The label also warns about rising platelet counts and possible fetal harm, so blood counts require monitoring.
Does it prevent strokes and clots? The trial measured phlebotomy avoidance and hematocrit control, not cardiovascular events. A benefit is plausible but was not directly demonstrated.
Should patients stop phlebotomy? No. This is a decision for a hematologist, and the drug was studied alongside standard care rather than as a replacement for it.
